He knows he was adopted from South Korea. The rest is a troubling mystery
Image: Family photo
Kelly Kasulis Cho
For most of his life, Aaron Grzegorczyk believed that his birth name was Cho Yong-kee. He thought he was born on April 28, 1988, in a clinic in Anyang, South Korea, about 11 miles south of Seoul. He was told that his mother, a 19-year-old unwed woman, had abandoned him a day after giving birth to him. In an initial physical exam, he was recorded as 'cute and alert.'
Less than five months later, he arrived into the arms of his adoptive Polish American parents in Bay City, Michigan. He was their first child, sensitive and artistic, and his birth mother had surrendered him so that he could have, as his adoption papers put it, 'an optimum future.'
Grzegorczyk never questioned this story until this past March. That's when his friend sent him an article detailing the South Korean government's admission to five decades of adoption fraud.
'I was reading it and I was just like, jaw open,' Grzegorczyk said. 'I had absolutely no idea about any of this.'
Immediately, he started digging into his past.
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Advertisement
Next
Stay
Close ✕
Ad loading
South Korea's adoption 'industry'
Earlier this year, a South Korean government-appointed, independent investigative commission released a damning report that for the first time admitted the country had allowed human rights abuses to occur in what it criticized as a decades-long 'profit-driven' adoption 'industry.'
An examination of dozens of cases between 1964 and 1999 found that some children were taken without their biological parents' consent, while others were given false birth names and fake background stories before being sent abroad for steep adoption fees. Some were sent without legally valid documents or with little to no screening of the adoptive family, and agencies often scurried to fulfill orders or quotas in what the report called the 'mass exportation of children to meet demand.'
'The long-standing intercountry adoption practices represent a failure of the government to uphold its responsibility to protect the fundamental human rights of its citizens,' South Korea's Truth and Reconciliation Commission said.
The TRC's conclusions were based on a partial review of 367 cases submitted by adoptees across 11 countries. It's unclear how many of the more than 200,000 Korean children estimated to have been adopted internationally since the end of the Korean War were sent abroad under unlawful pretenses, but experts say bad practices by adoption agencies were widespread. In some cases, the birth parents were lied to and told their child had died shortly after delivery.
'We have not seen one case where there is not an issue,' said Boon Young Han, one of several adoptees from Denmark who banded together as the Danish Korean Rights Group and successfully campaigned for the South Korean government to launch its investigation. Her organization has meticulously investigated more than 2,000 cases.
Grzegorczyk with his adoptive family in Michigan.
Image: Family photo
An 'existential crisis'
For Grzegorczyk, the recent news has thrown his entire life course into question. He was in his early teens when his adoptive mother told him that his birth mother had abandoned him - a moment he now refers to as his 'first existential crisis.'
'That was the very first mental and emotional issue that I ever confronted in my life,' he said.
South Korea had just risen out of widespread postwar poverty and was in the throes of its decades-long struggle for democratization when Grzegorczyk was born. The country had already massively transformed its economy, but it was not the Group of 20 nation it is today.
Grzegorczyk grew up feeling out of place in a predominantly White community, he said, and began having behavioral issues in his early teens. He attended graphic design college in 2006, but dropped out amid the 2008 financial crisis, fearing his degree would be useless for getting a job. He then worked for years as an emergency medical technician - a job so 'rough' that he was eventually diagnosed with post-traumatic stress disorder, he said.
Grzegorczyk began suffering from substance abuse issues. He quit his emergency responder career, which paid close to minimum wage, and resorted to selling drugs, he said. He got in trouble with the law and spent a few stints in jail.
'I can't say whether or not my adoptive parents are proud of how I turned out,' he said. ' … I've made the most of my life despite a lot of hardships, most of which I did bring on myself.'
He turned his life around in 2019, he said, when he found out he was expecting a child. He got sober and started a roofing apprenticeship.
'I finally got into a place where, I wouldn't call myself happy, but I am for the most part at peace,' he said during a Zoom call in April. 'Up until about five days ago, when I heard about all of this,' he added, his smile giving way to tears.
Grzegorczyk with his daughter, Isla.
Image: Family photo
Dizzying quests for the truth
For years, activists and adoptees have criticized adoption agencies in South Korea for being slow or outright uncooperative in sharing their adoption records. Several adoptees told The Washington Post that they've been searching for their complete records for years, bogged down in the bureaucracy of working with adoption agencies in South Korea as well as filing Freedom of Information Act requests in their home states.
'The documents are not just a piece of paper,' Han said. 'That is our one and only clue, our one and only opportunity, to trace back our original identity.'
South Korea recently ordered all adoption agencies to turn their files over to a government office called the National Center for the Rights of the Child, starting in July. The change could standardize birth family searches, Han said, but she also fears some documents will get lost in the transfer. Meanwhile, politicians are debating whether they'll investigate more adoption cases.
In Grzegorczyk's case, the paperwork his adoptive mother saved for him raises some red flags: The file does not include a police report detailing his abandonment, nor a relinquishment consent form signed by a birth parent. There is no name or address for the clinic he was supposedly left at as a newborn, and several fields on his forms are left blank. His family origin is also listed as 'Hanyang,' a placeholder term referring to Seoul.
'If it says 'Hanyang' in the document, then you know the name is falsified. It's incorrect,' Han said. 'It's like saying someone comes from Disneyland,' she added.
A page from the adoption file of Grzegorczyk, 37, born Cho Yong-kee on April 28, 1988, in Anyang, South Korea, with an identification bracelet that had been attached to him as a baby.
Image: Family photo
Hope for reunion
In mid-April, Grzegorczyk faced another twist: A worker at his adoption agency told him that she had spoken by phone with his purported birth mother, whom the employee said was 'happy to keep in touch' with him and had been 'waiting for a long time.' The worker asked Grzegorczyk to write her an introduction letter, which the agency confirmed it translated and sent days later. In the letter, he spoke fondly of his 5-year-old daughter, Isla, his brother and his sister - also a Korean adoptee - and his young nieces.
'I never tried to look for you because I didn't think you wanted to be found,' he wrote. ' … I have so much more to say and questions that I would like to ask you. But I don't want to overwhelm you. I was so happy to hear that you wanted to talk to me.'
But Grzegorczyk hasn't heard anything from his mother since. The adoption agency worker told him that his case will be turned over to the government office that is taking over adoptee records in July, and said his mother never responded to a second phone call.
He seemed resigned, asking the worker to give his contact information to her.
Driving his car back from Detroit in the middle of the night in mid-May, he looked forlorn in a video message, masking his disappointment in between jokes and grins.
'I never planned on hearing anything from anybody in the first place, my whole life,' he said, appearing to try to cheer himself up.
'Maybe my paperwork wasn't made up,' he added. 'Let's say it is 100 percent true. At the very least, I would understand.' | The Washington Post

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
By Maggie Fick LONDON (Reuters) -A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts say. New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry analysts. Total Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound. In the week ended May 23, U.S. Zepbound prescriptions exceeded Wegovy by nearly 175,000. By July 18, the gap was about 133,000. Early signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's growth. And then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 peak. Jorgensen said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August 6. That leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to deliver. She has an "overweight" rating on Novo's shares. "We thought this trajectory change (in new prescriptions) would get the shares moving, but not so far," Berenberg analyst Kerry Holford told Reuters. "I suspect investors are now waiting for the (second quarter) update - will they/won't they trim guidance range? I think they will trim the top." Berenberg has a "hold" rating on Novo. Novo did not respond to a request for comment. Investors and analysts note that the IQVIA prescription data is incomplete, because it does not capture sales of Wegovy through the company's direct-to-consumer platform, NovoCare, launched in March. They estimate the channel is still a small slice of overall Wegovy volume. "We would hope to see strong growth from the NovoCare channel but are cognizant that this may come at initially lower prices" due to discount offers, said Marcus Morris-Eyton, a portfolio manager at Alliance Bernstein, whose fund holds Novo shares. "Sentiment towards Novo Nordisk is currently exceptionally weak, but given low expectations, the low valuation and hopefully accelerating prescription data in (the second half of 2025) we believe the market is underestimating Novo's long term growth potential," he said. BRINGING BACK PATIENTS Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the U.S. in 2021. But supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under U.S. law when drugs are in shortage. Investor sentiment on Novo soured after the company lost ground to U.S. rival Eli Lilly, which launched Zepbound in late 2023. In its first full-year forecast downgrade since Wegovy's launch, Novo said in May it expected local-currency sales growth of 13–21%, down from a previous forecast of 16–24%. Operating profit growth is projected at 16–24%, versus 19–27% previously. Capturing more of the patients who had turned to compounded drugs is key to meeting those targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health. Analysts at Berenberg and UBS are sceptical these moves will provide enough momentum and expect that Novo will reduce or narrow its full-year guidance ranges, according to research notes. TD Cowen said the outcome was hard to predict due to limited visibility on NovoCare. Bank of America and Guggenheim said they did not expect another guidance cut and Barclays said it was unlikely. ($1 = 0.8513 euros)
Yahoo
5 minutes ago
- Yahoo
AXA wins UK court ruling against Santander over PPI claims
Frensh insurer AXA has won a legal case in a London court, resulting in a ruling of approximately £680m (€781.53m) against Santander for the mis-selling of payment protection insurance (PPI). The issue involved losses from mis-selling complaints related to PPI policies underwritten by two companies acquired by AXA from Genworth in 2015. These policies were originally sold by a company that Santander acquired in 2009. The legal proceedings initiated by AXA in the High Court of London in 2021 were prompted by losses associated with more than 650,000 customer complaints regarding PPI policies, with banks having disbursed around £40bn in compensation, according to Reuters. AXA, which assumed responsibility for these liabilities following its acquisition of two Genworth units in 2015, has already paid nearly £500m in consumer redress and over £70m related to complaints, Judge Julia Dias said in her ruling. In her judgement, Judge Dias confirmed that AXA "has a valid claim for an indemnity" against Santander Insurance Services UK concerning the payments made for redress and fees associated with the ombudsman. Legal representatives for AXA at Quinn Emanuel indicated that the ruling's value is estimated at £675m. However, an AXA spokesperson clarified that the company would only receive a portion of the total amount awarded, as Genworth has already compensated AXA for a significant share of the losses incurred from the mis-selling. Genworth Financial stated that it anticipates receiving around $750m, contingent on the current exchange rate. In response to the ruling, a spokesperson for Santander expressed disagreement with the court's decision and indicated plans to appeal. The spokesperson further stated: "We do not expect the net impact of the judgment to be material for Santander given provisions already made and the potential legal actions available. 'No customers have suffered loss as a consequence of the claim brought by AXA France or the judgment, nor does it impact upon past redress paid to customers for PPI complaints." "AXA wins UK court ruling against Santander over PPI claims" was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Best CD rates today, July 28, 2025 (Lock in up to 5.5% APY)
Today's CD rates still hover well above the national average. The Federal Reserve reduced its target interest rate three times in 2024. This had a ripple effect on deposit account rates, which means now could be your last chance to lock in today's high rates with a certificate of deposit (CD). Here's a look at today's best CD rates and where you can find the best offers. Best CD rates today As of July 28, 2025, the highest CD rate is 5.5% APY, offered by Gainbridge® on its 5-year CD. There is a $1000 minimum opening deposit required. Here is a look at some of the best CD rates available today from our verified partners. This embedded content is not available in your region. National average CD rates If you're considering a CD, these rates are some of the highest available, especially when compared to the national average rates, which are significantly lower. It's also worth noting that online banks and credit unions generally offer more competitive rates compared to traditional brick-and-mortar banks. Read more: What is a good CD rate? Here's a look at the average CD rate by term as of June 2025 (the most recent data available from the FDIC): The highest national average interest rate for CDs stands at 1.77% for a 1-year term. However, in general, today's average CD rates represent some of the highest seen in nearly two decades, largely due to the Federal Reserve's efforts to combat inflation by keeping interest rates elevated. How to find the best CD rates If you're thinking about opening a CD, it's important to choose one with a high APY and term length that matches your financial goals. Here are some tips for finding the best CD rates and accounts that match your needs: Shop around: It's a good idea to evaluate CD rates from a variety of financial institutions and compare your options before settling on an account. You can easily compare CD rates online. Consider online banks: Online banks tend to have lower overhead costs, which allows them to offer higher interest rates on CDs. In fact, online banks often have the most competitive rates available. Check minimum deposit requirements: Higher CD rates might come with higher minimum deposit requirements, so make sure the amount you plan to deposit aligns with the requirements to get the best rate. Review account terms and conditions: Beyond the CD's rate, look at terms for early withdrawal penalties and auto-renewal policies. Some CDs offer better terms for flexibility, such as no-penalty CDs, which allow you to withdraw your funds without a fee before the maturity date.